Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Lowered to Hold at Stifel Nicolaus

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by equities researchers at Stifel Nicolaus from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, The Fly reports. They currently have a $23.00 target price on the specialty pharmaceutical company’s stock, down from their prior target price of $55.00. Stifel Nicolaus’ target price indicates a potential upside of 5.89% from the stock’s previous close.

Several other analysts have also recently commented on the company. TheStreet cut Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Thursday, August 29th. ValuEngine cut Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. BidaskClub raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. Mizuho reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, August 7th. Finally, Zacks Investment Research raised Supernus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $46.50.

Shares of SUPN stock traded up $0.57 during mid-day trading on Thursday, hitting $21.72. 1,010,300 shares of the stock traded hands, compared to its average volume of 579,923. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of 10.60, a price-to-earnings-growth ratio of 1.02 and a beta of 1.63. The company’s 50-day simple moving average is $26.80 and its 200-day simple moving average is $30.29. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.53 and a current ratio of 2.72. Supernus Pharmaceuticals has a twelve month low of $19.35 and a twelve month high of $49.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $0.54 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.59 by ($0.05). The business had revenue of $102.14 million during the quarter, compared to analyst estimates of $108.70 million. Supernus Pharmaceuticals had a return on equity of 21.80% and a net margin of 25.92%. The business’s quarterly revenue was down .8% on a year-over-year basis. During the same period last year, the business earned $0.52 EPS. Analysts forecast that Supernus Pharmaceuticals will post 2.14 earnings per share for the current year.

In other news, CEO Jack A. Khattar acquired 7,200 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was acquired at an average cost of $26.39 per share, for a total transaction of $190,008.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.57% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the stock. Patriot Financial Group Insurance Agency LLC purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter worth $33,000. Private Capital Group LLC raised its holdings in shares of Supernus Pharmaceuticals by 108.0% during the second quarter. Private Capital Group LLC now owns 1,379 shares of the specialty pharmaceutical company’s stock worth $83,000 after acquiring an additional 716 shares in the last quarter. Point72 Hong Kong Ltd raised its holdings in Supernus Pharmaceuticals by 324.1% during the second quarter. Point72 Hong Kong Ltd now owns 1,692 shares of the specialty pharmaceutical company’s stock valued at $56,000 after buying an additional 1,293 shares in the last quarter. First Mercantile Trust Co. raised its holdings in Supernus Pharmaceuticals by 31.5% during the third quarter. First Mercantile Trust Co. now owns 2,173 shares of the specialty pharmaceutical company’s stock valued at $60,000 after buying an additional 520 shares in the last quarter. Finally, Redhawk Wealth Advisors Inc. bought a new position in Supernus Pharmaceuticals during the second quarter valued at about $202,000. Institutional investors and hedge funds own 99.14% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Recommended Story: Why is a lock-up period needed for an IPO?

The Fly

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.